Clinical trial · Observational

Predicting Response to Chemotherapy in Colorectal Cancer Via Multi-dimensional Analyses of the Tumor Associated Neutrophils

Zhongshan Hospital，Fudan University

NCT06495827CI-TRIAL-00078737completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

A single biomarker is not adequate to identify patients with colorectal cancer (CRC) who have the potential to benefit from adjuvant therapy, presumably owing to the complexity of tumor-infiltrating immune cells (TIICs). The density and spatial organization of TIICs has not been definitely established to explore their predictive value. This study aimed to investigate the prognostic significance of TIICs and its biological predictive value in CRC.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Tumor Associated Neutrophils	—	UNRESOLVED	—

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
No different intenvention	Other	—	UNRESOLVED

Design

Arms and outcomes

Arms (2)

label
response cohort
description
CRC patients with response status after chemotherapy
interventionNames
1. Other: No different intenvention
label
resistance cohort
description
CRC patients with resistance status after chemotherapy
interventionNames
1. Other: No different intenvention

Primary outcomes (1)

measure
PFS
timeFrame
From date of operation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months
description
From date of operation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months

Eligibility

Eligibility (as posted)

Sex: All

Show eligibility criteria text

Inclusion Criteria:

1. Voluntarily sign a written ICF.
2. The Eastern Cancer Collaborative Organization (ECOG) has a physical fitness score of 0 or 1.
3. The expected survival period is ≥ 3 months.

5\. Subjects diagnosed with metastatic colorectal adenocarcinoma by histology or cytology.

6\. Colorectal cancer patients who have not received systematic anti-tumor therapy in the past.

Exclusion Criteria:

1. Subjects suffered from other malignant tumors within 3 years before enrollment, except for cured local tumors (such as basal cell skin cancer, squamous cell skin cancer, superficial bladder cancer, cervical carcinoma in situ, etc.).
2. Simultaneously enroll in another clinical study, unless it is an observational, non-interference clinical study or a follow-up period of an intervention study.
3. Received systematic anti-tumor therapy (chemotherapy) within 3 weeks prior to the first administration

References

Publications (0)

Data not yet available

No reference posted for this study.